NEW YORK (GenomeWeb News) – Proteros Biostructures said today that it has agreed to investigate potential small molecule lead compounds for Johnson & Johnson Pharmaceutical Research and Development (J&JPRD).
Under the partnership agreement, Proteros will use its lead discovery service, which employs structural biology, screening of an in-house compound and fragment library, compound profiling, and medicinal chemistry activities, to find leads against a specific target provided by J&JPRD.
The Martinsried, Germany-based firm said its service speeds up protein structure analysis and structure-based discovery with its expertise and processes for crystallography and fragment-based lead generation.
Financial terms of the agreement were not released.